Multi-component automated collection – novel tendency in blood donating

Česká verzia

Authors: R. Procházková
Authors place of work: Transfuzní oddělení, Krajská nemocnice Liberec, přednosta prim. MUDr. Renata Procházková
Published in the journal: Vnitř Lék 2005; 51(3): 320-326
Category: Reviews

Summary

Multi-component blood collection represents a new tendency in transfusiology. Modern blood separators allows concomitant collection of erythrocytes, thrombocytes or plasma in various combinations from one blood donor in one session, with a result of high quality standardised transfusion preparations in the final form. The method represents the alternative to full blood donating, brings advantages for patients and transfusion sites. An application of more transfusion preparations from one donor decreases risks of haemotherapy in poly-transfusion patients, the method brings flexibility and rational utilisation of donor base for transfusion sites. Currently the method represents a matter of interest of leading world-known transfusion professionals, questions regarding inclusion criteria for blood donors, the influence of this type of blood collection on blood donors and the quality of products obtained are intensively studied. The author gives review of current state of the topic.

Key words:
multi-component blood collection – apheresis – inclusion criteria for blood donor – transfusion – quality of transfusion preparations – effectivity of the method

Zdroje

1. Adam Z, Vorlíček J, Koptíková J. Obecná onkologie a podpůrná léčba. Praha: Grada 2003.

2. Bandarenko N. The selection and care of multiple component apheresis donors: a medical perspective. Annual meeting AABB Symposium: Orlando, USA 2002.

3. Bláha M, Turek P, Gašová Z et al. Hemaferéza v České republice. Vnitř Lék 2003; 49(2): 153–154.

4. Bláha M et al. Rizika hemaferéz. Hematologie a transfuziologie 1992; 4: 33–42.

5. Blanco L. Tailored collection of multicomponent by apheresis. Transfus Apher Sci 2002; 27(2): 123–127.

6. Bolan CD, Greer SE, Cecco SA et al. Comprehensive analysis of citrat effects during platepheresis in normal donors. Transfusion 2001; 41(9): 1165–1171.

7. Čermák J, Brabec V. Klinický význam vyšetření hladiny cirkulujících transferinových receptorů v séru. Vnitř Lék 1999; 8: 468–472.

8. Elfath MD, Whitley P, Jacobson MS et al. Evaluation of an automated systém for the collection of packed RBCs, platelets, and plazma. Transfusion 2000; 40(10): 1214–1222.

9. Furuta M, Shimizu T, Mizuno S et al. Clinical evaluation of repeat apheresis donors in Japan. Vox Sanq 1999; 77(1): 17–23.

10. Gable RG, Edwards RL. The use of platelet concentrates versus platepheresis – the donor perspective. Transfusion 2001; 41: 727–729.

11. Gemmell C. Activation of platelets by in vitro whole blood contact with materials: Increases in microparticle, procoagulant activity and soluble P-selectin blood levels. J Biomater Sci Polym Ed 2001; 12(8): 933–943.

12. Goodnough LT, Shander A, Brecher ME. Transfusion medicine: looking to the future. Lancet 2003; 361(9352): 161–188.

13. Guide to the preparation, use and quality assurance of blood components.9^th ed. Strasburg: Council of Europe Publishing 2003.

14. Hocker P. Red cell apheresis in autologous preoperative blood donation. Transf Apher Sci 2001; 24(1): 75–78.

15. Hogler W, Mayer W, Messmer C et al. Prolonged iron depletion after allogenetic 2-unit apheresis. Transfusion 2001; 41(5): 602–605.

16. Holme S, Elfath MD, Whitley P. Evaluation of in vivo and in vitro quality of apheresis collected RBC stored for 42 days. Vox Sanq 1998; 75(3): 212–217.

17. Chrobák L. Mikrocytární a hypochromní anémie. Vnitř Lék 2001; 47(3): 166–174.

18. Koubek K. CD nomenklatura leukocytárních antigenů. Vnitř Lék 2003; 49(1): 66–72.

19. Krailadsiri P, Seghatchian J, Williamson LM. Platelet storage lession of WBC-reduced, pooled buffy coat-derived platelet concentrates prepared in three in-process filter/storage bag combinations. Transfusion 2001; 41(2): 243–250.

20. Krailadsiri P, Seghatchian J. Effect of processing and storage on platelet activation, cellular injury and microvesiculation. Transf Apher Sci 2001; 24(3): 237–238.

21. Krailadsiri, P., Seghatchian, J.: Are all leucodepleted platelet concentrates equivalent? Comparison of Cobe LRS Turbo, Haemonetics MCS+ LD, and filtered pooled buffy-coat-derived platelets. Vox Sanq 2000; 78(3): 171–175.

22. Kubešová H, Krahulcová E, Kiss I et al. Substituce krevními deriváty v období dřeňové aplázie u nemocných po agresivní chemoterapii zhoubných hematologických onemocnění. Vnitř Lék 1993; 39(5): 430–436.

23. Leitner GC, Stohlawetz PJ, Stiegler PJ et al. Quality of packed red blood cells and platelet concentrates by multicomponent collection using the MCS Plus device. J Clin Apheresis 2003; 18(1): 21–25.

24. Loudová M, Krejsek J, Kopecký O et al. Cytoimunofluorometrie a její využití v detekci aktivované destičky. Vnitř Lék 2001; 47(3): 175–180.

25. Makar YF, Butler MO, Cockersole GM et al. National audit of citrate toxicity in plateletpheresis donors. Transfus Med 2002; 12(3): 187–191.

26. Matthes GA. Options and cost effectiveness of multicomponent blood collection. Transf Apher Sci 2002; 27(2): 115–121.

27. Moog R, Bartsch R, Muller N. Concurent collection of in–line filtered platelets and red cells by apheresis. Ann Hematol 2002; 81(6): 322–325.

28. Moog R, Franck V, Pierce JA et al. Evaluation of a concurrent multicomponent collection system for the collection and storage of WBC – reduced RBC apheresis concentrates. Transfusion 2001; 41(9): 1159–1164.

29. Moore SB, Winters JL. Multiple blood donations and iron deficiency in patients with Restless legs syndrome. Mayo Clin Proc 2003; 78(5): 654–656.

30. Novosad J, Kodydková K, Krejsek J. Apoptóza, její mechanizmy a medicínský význam. I. Definice apoptózy a její průběh na buněčné úrovni. Vnitř Lék 2001; 47(6): 381–386.

31. Novosad J, Kodydková K, Krejsek J. Apoptóza, její mechanizmy a medicínský význam. II. Poruchy regulace apoptózy a jejich souvislost s rozvojem onemocnění. Vnitř Lék 2001; 47(6): 387–390.

32. Quendro I, Moog R, Muller N. A questionainre: will plateletpheresis donors accept multicomponent donation? Transfus Apher Sci 2002; 27(2): 95–99.

33. Recommendations for collecting red blood cells by automated apheresis methods. FDA Draft Guidance for Industry (Docket Number 98D–0545). Rockville, MD: FDA July 1998.

34. Regan F, Teesdale P, Garner S et al. Comparsion of in vivo red cell survival of donations collected by Haemonetics MCS versus conventional collection. Transfus Med 1997; 7(1): 25–28.

35. Seghatchian J, Krailadsiri P. Red cell storage lesion assesed by the levels of potassium, hemoglobin and annexin V in supernatantant. Transfus Apher Sci 2002; 26(2): 121–127.

36. Seghatchian J, Krailadsiri P, Dilger P et al. Cytokines as quality indicators of leucoreduced red cell concentrates. Transfus Apher Sci 2002; 26(1): 43–46.

37. Seghatchian MJ, Wadhwa M, Thorpe R. Cytokines in Platelet Concentrates: A Comparsion of Apheresis Platelet (Haemonetics) and Filtered and Unfiltered Pooled Buffy – Coat Derived Platelet Concentrates. Transfus Sci 1997; 18(1): 103–107.

38. Shi PA, Ness PM. Two–unit red cell apheresis and int potential advatages over traditional whole–blood donation. Transfusion 1999; 39(2): 218–225.

39. Silberman S. Platelets: preparations, transfusion modifications and substitutes. Arch Pathol Lab Med 1999; 123(10): 889–894.

40. Stohlawetz PO, Hergovich N, Stiegler G et al. Differential induction of P selectin on platelets by two cell separators during platepheresis and the effect on the release of soluble P–selectin. Transfusion 1998; 38(3): 24–30.

41. Straub J, Kolešková E, Haber J. Sideropenická anémie jako projev selektivní malabsopce železa. Vnitř Lék 2001; 47(7): 493–495.

42. Ščudla V, Adam Z, Ščudlová M. Současné možnosti diagnostiky a léčby anémie chronických chorob. Vnitř Lék 2001; 47(6): 400–406.

43. Tzima E, Walker JH. Platelet annexin V: the ins and outs. Platelets 2000; 11: 245–251

44. Valbonesi M, Bruni R, Bo A et al. Double platepheresis (DPA) and tailored RBC collection with the Excel-Pro: preliminary results. Transf Apher Sci 2001; 24(1): 71–73.

45. Vášová I, Mayer J. Biologické účinky alogenních leukocytů a deleukotizace buněčných krevních derivátů. Vnitř Lék 1995; 41(10): 713–718.

46. Wadhwa M, Seghatchian MJ, Dilger P et al. Cytokines in WBC–reduced apheresis PCs during storage: a comparsion of two WBC-reduction methods. Transfusion 2000; 40(9): 1118–1126.

47. Western KH, Videm V. Donor neutrophil function after plateletpheresis. Transfusion 2000; 40(11): 1414–1418.

48. Zeiler TA, Kretschmer V. Automated blood component collection with the MCS 3p cell separator: evaluation of three protocols for buffy coat-poor and white cellreduced packed red cells and plazma. Transfusion 1997; 37(8): 791–797.

49. Zingsem J, Weisbach V, Zimmermann R et al. Preparation of FFP as byproduct of plateletpheresis. Transfusion 2001; 42(1): 81–86.